Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019;15(3):549-559.
doi: 10.1080/21645515.2019.1568159. Epub 2019 Feb 15.

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

R Rupp  1 , D Hurley  2 , S Grayson  3 , J Li  3 , K Nolan  3 , R D McFetridge  3 , J Hartzel  3 , C Abeygunawardana  3 , M Winters  3 , H Pujar  3 , P Benner  3 , L Musey  3
Affiliations
Clinical Trial

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

R Rupp et al. Hum Vaccin Immunother. 2019.

Abstract

Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant.

Methods: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12-15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants.

Results: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant.

Conclusion: PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.

Keywords: Pneumococcal conjugate vaccine; immunogenicity; safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject Disposition in Study #1 (PCV15-Formulation A).
Figure 2.
Figure 2.
Postdose 3 IgG GMCs Figure 1: Subject Disposition in Study #1 (PCV15-Formulation A) (Infant Per-Protocol Population). ● Lot 1 = 1x:1x composition (2 μg/dose polysaccharide: 125 μg/dose adjuvant; except 6B)● Lot 2 = 0.5x:2x composition (1 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● Lot 3 = 1x:2x composition (2 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● Lot 4 = 2x:2x composition (4 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● PCV13 = Prevnar 13● IgG=immunoglobulin G; GMC=geometric mean concentration; PCV pneumococcal polysaccharide vaccine
Figure 3.
Figure 3.
Postdose 3 IgG Response Rates in Study #1 (PCV15-Formulation A) (Infant Per-Protocol Population). ● Lot 1 = 1x:1x composition (2 μg/dose polysaccharide: 125 μg/dose adjuvant; except 6B)● Lot 2 = 0.5x:2x composition (1 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● Lot 3 = 1x:2x composition (2 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● Lot 4 = 2x:2x composition (4 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● PCV13 = Prevnar 13● IgG=immunoglobulin G; GMC=geometric mean concentration; PCV pneumococcal polysaccharide vaccine
Figure 4.
Figure 4.
Subject Disposition in Study #2 (PCV15-Formulation B).
Figure 5.
Figure 5.
Postdose 3 IgG GMCs in Study #2 (PCV15-Formulation B) (Infant Per-Protocol Population). ● Lot 5 = 1x:1x composition (2 μg/dose polysaccharide: 125 μg/dose adjuvant; except 6B)● Lot 6 = 2x:2x composition (4 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● PCV13 = Prevnar 13● IgG=immunoglobulin G; GMC=geometric mean concentration; PCV pneumococcal polysaccharide vaccine
Figure 6.
Figure 6.
Postdose 3 IgG Response Rates in Study #2 (PCV15-Formulation B) (Infant Per-Protocol Population). ● Lot 5 = 1x:1x composition (2 μg/dose polysaccharide: 125 μg/dose adjuvant; except 6B)● Lot 6 = 2x:2x composition (4 μg/dose polysaccharide: 250 μg/dose adjuvant; except 6B)● PCV13 = Prevnar 13● IgG=immunoglobulin G; GMC=geometric mean concentration; PCV pneumococcal polysaccharide vaccine
See this image and copyright information in PMC

References

    1. Cherian T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine. 2007;25:6557–64. doi:10.1016/j.vaccine.2007.06.044. - DOI - PubMed
    1. O’Brien K, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi:10.1016/S0140-6736(09)61204-6. - DOI - PubMed
    1. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20 Supple 5:45–51. doi:10.1111/1469-0691.12461. - DOI - PubMed
    1. Arditi M, Mason EO Jr, Bradley JS, Tan TQ, Barson WJ, Schutze GE, Wald ER, Givner LB, Kim KS, Yogev R, et al Three-year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. 1998;102(5):1087–1097. - PubMed
    1. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources